NCT04140123View on ClinicalTrials.gov

Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

August 3, 2021

Study Completion Date

August 3, 2021

Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
DRUG

ZSP1601

ZSP1601 tablets be taken orally for 28 days.

DRUG

ZSP1601 Placebo

Subjects will receive matching placebo of ZSP1601

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY

NCT04140123 - Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH) | Biotech Hunter | Biotech Hunter